Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MCAC Panel Recommends Medicare Coverage For Stem Cell Therapy

This article was originally published in The Gray Sheet

Executive Summary

Autologous stem cell transplantation (ASCT) in combination with high dose chemotherapy should receive Medicare coverage for treatment of multiple myeloma, the Drugs, Biologics and Therapeutics Panel of the Medicare Coverage Advisory Committee unanimously recommended Sept. 16 in a 5-0 vote.

You may also be interested in...



MCAC Panel Decision Postponed Following Chair's "No Confidence" Vote

A dissenting opinion by Medicare Coverage Advisory Committee's Drugs, Biologics, and Therapeutics Panel Chair Thomas Holohan, MD, Department of Veterans Affairs, effectively nullified a unanimous recommendation by his panel supporting coverage of stem cell transplantation for multiple myeloma.

MCAC Panel Decision Postponed Following Chair's "No Confidence" Vote

A dissenting opinion by Medicare Coverage Advisory Committee's Drugs, Biologics, and Therapeutics Panel Chair Thomas Holohan, MD, Department of Veterans Affairs, effectively nullified a unanimous recommendation by his panel supporting coverage of stem cell transplantation for multiple myeloma.

Medicare Coverage Of Tumor Assays Should Be Monitored - MCAC Panel

Human tumor assay systems demonstrate clinical utility for certain patients and hold promise as a tool for treating a broad range of cancers, the Laboratory and Diagnostic Services Panel of the Medicare Coverage Advisory Committee agreed at its Nov. 15-16 meeting in Baltimore.

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel